Gregory D. Huhn, MD

Associate Professor, Infectious Diseases
The Ruth M. Rothstein CORE Center
Chicago, IL

Disclosure: Gilead: Consultant, Grant/Research Support
Janssen: Consultant, Grant/Research Support
Proteus: Grant/Research Support
US National Institutes of Health: Research Grant or Support
ViiV: Consultant, Grant/Research Support

Presentation(s):

• 887 - High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial

  Thursday, October 3
  4:15 PM – 4:30 PM